Clinical Trial Update: CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors [Phase 1]

View source ↗

Summary

Sponsor Mingzhi Zhang is conducting a Phase 1 CAR-T cell therapy trial for recurrent/refractory malignant hematological and lymphatic tumors, currently not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphomas

Drugs mentioned

• CAR-T cell therapy

Snippet

Sponsor: Mingzhi Zhang | Conditions: CAR-T Cell Therapy, Lymphomas | Phase 1 | Status: NOT_YET_RECRUITING